Christopher Hergott

Buffalo-born. Postdoctoral fellow in Ebert Lab @danafarber. Hematopathologist @BWHPath. MD and PhD from @PennMedicine. Opinions my own, open to persuasion.

[Weill Cornell Medicine Pathology @WCMCPathology]

Please share:

The @WCMCPathology dep't in New York City offers a one-year ACGME-approved #Hematopathology Fellowship for 2027-28 under the directorship of Dr. Sanjay Patel (@SanjayPatelMD)! @pathologysocial
#PathTwitter

Learn more and apply today:
https://t.co/CpXdYni5v3

[Christopher Hergott @CBHergott]

Some very cool experiments in here.

[Science Magazine @ScienceMagazine]

The heart’s constant beating may actively suppress tumor growth in cardiac tissues, a new Science study reports. This is because cellular pathways in these tissues alter gene regulation in cancer cells to keep them from proliferating.

The findings shed light on the role of mechanical forces in protecting the heart from cancer and may pave the way to new cancer therapies based on mechanical stimulation.

Learn more: https://t.co/aqu8ZcPjaI

[Sarah J. Wu, MD, PhD @sarahjwu]

Just published! Read all about our cohort of mature pDC proliferations and secondary BPDCN! #MPDCP #BPDCN #hemepath @MGBpathology @lane_andy @CBHergott @LuskinMarlise @ShaiShimony

https://t.co/HDmmIOf6Vy

[Andy Lane @lane_andy]

The Clinicopathologic and Genomic Features of Mature Versus ... : The American Journal of Surgical Pathology | @sarahjwu, Sam Sadigh, #BPDCN https://t.co/XbrRLuW9k8

[Truthstream Media @truthstreamnews]

“We stole all your knowledge and art, and now we’re gonna put a meter on it and sell it back to you. You’re welcome.”

[Mick Milsom @MilsomMick]

https://t.co/PdVEafKXbM
Important pub from @TrowbridgeLab for those whose institutions shift to X-ray source for BMT conditioning , published in @ISEHSociety journal Exp Hem. You can’t simply give apparent equivalent doses of gamma and x-ray and get the same outcome.

[Eric Pietras @pietras_eric]

Our newest preprint is now online! We lift up the hood on TET2 mutant clonal hematopoiesis and show that oxidative metabolism is a critical feature of TET2 deficient HSPC - with compensatory redox control as a potential vulnerability.
https://t.co/t8wdEmvSrp

[Christopher Hergott @CBHergott]

Happy to see this out. Co-led with @petergkim at @CellChemBiol.
#EvansMDS @bloodcancerutd #leusm #clonalhematopoiesis
@DanaFarber @MGBpathology
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis: Cell Chemical Biology https://t.co/V4iRlAO0rg

[Blood Cancer United @BloodCancerUtd]

This research starts with understanding the “why.” ❤️

With support from one of our early career scientist grants, Dr. Zuzana Tothova is studying how changes inside blood cells can lead to blood cancers like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

A better understanding of the earliest blood cell changes leading to cancer will help scientists find better, more targeted ways to treat it 👉 https://t.co/MiUDB5pPGt

[David Faux @DFauxy]

Turns out Sean McDermott’s best trait as a Bills coach was protecting everyone from Terry Pegula.
A true defensive genius.

[Daniel Starczynowski @dstarczynowski]

New paper in @CellChemBiol from Starczynowski Lab → congrats to first author Emma Uible (@emmavontz)!
"CASP1 is a non-enzymatic dependency in MDS/AML that restrains excessive inflammatory signaling"
https://t.co/AOpyjHYK9q

[Jennifer Guerriero, PhD @JennGuerriero]

PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the aforementioned M1/M2 states. M1/M2 language causes confusion and sets the field back. Refer to your macrophages by the molecules they express and the cytokines they make.

[Christopher Hergott @CBHergott]

Amen

[Sanjay Patel, MD @SanjayPatelMD]

1/ Reflecting on #ASH25, I can’t help but lament the apparent persistent addiction the myeloid neoplasm community still seems to have with the concept of a cell intrinsic/autonomous basis for clonal evolution and development of MDS/AML.

[Christopher Hergott @CBHergott]

This would force everyone to either: A) Do residency in a specialty covered in core rotations, or B) Apply to residency with minimal (elective) experience in field of interest, no?

[Zeke Emanuel @ZekeEmanuel]

Who gets to be a doctor in America is about to change.

Trump’s new federal student loan caps will push lower-income students out of medicine and make the physician shortage worse. It's time to shorten medical school to three years.

https://t.co/VrYXcTkeed

[Jake Bledsoe @jake_bledsoe]

Check out our study on the genomic features of pediatric CTCL, published @ModernPathology

We found recurrent TK gene fusions including JAK2 in most mycosis fungoides, TYK2 in LyP and pcALCL, some novel fusions. #hemepath #pedipath #pathx

Free link: https://t.co/wcxTzVgs1o

[Ivan Zanoni @Lo_Zanzi]

#InflammasomePower! How is NLPR3 primed & activated in chronic non-communicable inflammatory diseases? With Oceane &co we show that chronic oxPAPC signaling drives NRF2 activation that primes & activates NLRP3 sustaining #atherosclerosis in mice & humans! https://t.co/mV4S40suiG

[calliecoombs @calliecoombsmd]

👀👀 Revumenib now FDA approved for NPM1 mutated relapsed AML #amlsm

[Rossana Melo @RossanaMelo5]

Here's a high-resolution peek at #neutrophils isolated straight from the human bloodstream, captured in stunning detail with #electronmicroscopy and colorized! 🤩 #MicroscopyMonday

[Talha Badar @TalhaBadarMD]

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia https://t.co/YRlQ3N7OW6

70 cases of B-cell #ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia.
Dismal outcome with median OS 4.9 months.
#leusm @BloodPortfolio

[David Steensma, MD @DavidSteensma]

With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1